Biomarin Pharmaceutical (BMRN) Total Debt Growth (3y) (2013 - 2024)
Biomarin Pharmaceutical (BMRN) Total Debt Growth (3y) (2013 - 2024) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Total Debt Growth (3y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
- |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
6.94% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
- |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
- |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Biomarin Pharmaceutical |
10.52 Bn |
8.29 Bn |
571.21 Mn |
- |
| Date | Value |
|---|
| Jun 30, 2024 |
148.62% |
| Mar 31, 2024 |
152.25% |
| Sep 30, 2022 |
41.45% |
| Jun 30, 2022 |
44.51% |
| Mar 31, 2022 |
-10.12% |
| Sep 30, 2021 |
-17.62% |
| Jun 30, 2021 |
-55.68% |
| Mar 31, 2021 |
-56.15% |
| Jun 30, 2020 |
88.69% |
| Mar 31, 2020 |
100.71% |
| Dec 31, 2019 |
98.42% |
| Sep 30, 2019 |
-23.64% |
| Jun 30, 2019 |
-40.79% |
| Mar 31, 2019 |
-3.29% |
| Sep 30, 2018 |
-2.94% |
| Jun 30, 2018 |
59.35% |
| Mar 31, 2018 |
69.29% |
| Dec 31, 2017 |
139.71% |
| Jun 30, 2017 |
332.07% |
| Mar 31, 2017 |
215.30% |
